Fleming, Hawthorn team up to expand sales of CaloMist

ST. LOUIS Fleming Pharmaceuticals has announced a partnership with Hawthorn Pharmaceuticals to expand the sales reach of Fleming’s newly introduced drug, CaloMist. The drug, which is a once-daily Vitamin B12 nasal spray, is the first and only approved by the Food and Drug Administration to treat Vitamin B12 deficiency.

Under the agreement, Hawthorn will use its nationwide sales force to promote the product in every major metropolitan market in the U.S. The drug will be promoted as an alternative to intramuscular injections of the vitamin as the way to treat Vitamin B12 deficiency.

“We are thrilled to be working in concert with Fleming Pharmaceuticals on CaloMist” said Chris Smith, executive vice president of sales for Hawthorn Pharmaceuticals. “We know our sales force and physician relationships will bring real value and help build sales for this important new way to manage Vitamin B12 deficiency.”

The drug was released in December 2007 and is currently available by prescription.